IIB-IVA期宫颈癌每周顺铂联合紫杉醇新辅助化疗后放化疗与单纯放化疗的结局与副作用比较:随机对照试验研究方案
本研究为前瞻性、随机、开放标签、多中心III期试验,计划纳入300例IIB-IVA期宫颈癌患者,1:1随机分组。研究组接受每周剂量密集顺铂(40 mg/m2)联合紫杉醇(60 mg/m2)新辅助化疗4周期后行同步放化疗(45 Gy/5周同步每周顺铂40 mg/m2)加图像引导自适应近距离放疗;对照组仅行同步放化疗。主要终点为2年无病生存率,次要终点包括5年总生存率和无病生存率、治疗完成后3个月缓解率、III/IV级不良反应、生活质量及潜在生物标志物。
要点
- 研究针对IIB-IVA期宫颈癌,比较每周TP方案新辅助化疗后同步放化疗与单纯同步放化疗。
- 主要终点为2年无病生存率,假设同步放化疗组为65%、新辅助化疗后放化疗组为80%。
- 研究组新辅助化疗为每周顺铂40 mg/m2联合紫杉醇60 mg/m2,共4周期。
核心结论
- 研究数据将用于确定每周TP方案新辅助化疗后同步放化疗是否可能成为局部晚期宫颈癌的优化治疗。
研究设计与样本
- 前瞻性、随机、开放标签、多中心III期研究,计划纳入300例IIB-IVA期宫颈癌患者,按1:1比例随机分配至研究组或对照组。
主要发现
- 基于同步放化疗组2年无病生存率65%和新辅助化疗后放化疗组80%的假设,并考虑8%失访率、双侧5%I类错误概率和80%把握度,共需入组300例。
关键数值与推荐
- 研究组:每周剂量密集顺铂(40 mg/m2)联合紫杉醇(60 mg/m2),共4周期,随后行同步放化疗(45 Gy/5周同步每周顺铂40 mg/m2)加图像引导自适应近距离放疗。
- 对照组:行同步放化疗治疗。
- 主要终点为2年无病生存率;次要终点包括5年总生存率和无病生存率、治疗完成后3个月缓解率、III/IV级不良反应、生活质量及潜在预测治疗反应的生物标志物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, the standard treatment for locally advanced cervical cancer is concurrent chemoradiation (CCRT). The effect of neoadjuvant chemotherapy in advanced cervical cancer is controversial. Studies have shown that the addition of a weekly regimen of neoadjuvant chemotherapy (NACT) followed by CCRT may be superior to a thrice-weekly regimen of NACT and CCRT. Among patients who had not received prior cisplatin, a cisplatin and paclitaxel (TP) regimen resulted in longer overall survival than other regimens. This study aims to investigate the feasibility, safety, and efficacy of NACT with weekly TP followed by CCRT. METHODS: This is a prospective, randomized, open-labeled, multicentered phase III study. Based on a 65% of 2-year disease-free survival (DFS) rate in the CCRT group and 80% of that in NACT followed by CCRT group, and on prerequisite conditions including an 8% loss to follow-up, a two-sided 5% of type I error probability, and an 80% of power, a total of 300 cases were required for enrollment. Patients with IIB-IVA cervical cancer will be randomly allocated in a 1:1 ratio to one of two intervention arms. In the study arm, patients will receive dose-dense cisplatin (40 mg/m2) and paclitaxel (60 mg/m2) weekly for 4 cycles followed by CCRT (45 Gy in 5 weeks concurrent with cisplatin 40 mg/m2 weekly) plus image-guided adaptive brachytherapy (IGBRT). In the control arm, patients will undergo CCRT treatment. The primary endpoint of the study is 2-year disease-free survival (DFS); the secondary endpoints are 5-year overall survival (OS) and disease-free survival (DFS), the response rate 3 months after treatment completion, grade III/IV adverse effects, and quality of life, and potential biomarkers for predicting treatment response will also be studied. DISCUSSION: The data gathered from the study will be used to determine whether NACT with weekly TP followed by CCRT may become an optimized treatment for locally advanced cervical cancer. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1900025327. Registered on 24 August 2019. medresman.org.cn ChiCTR1900025326.
引用
- Li J, Liu H, Li Y, et al. Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB-IVA cervical cancer: study protocol for a randomized controlled trial. Trials. 2022. PMID: 35012634. doi:10.1186/s13063-021-05986-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。